Enterprise Value
-1.068M
Cash
117.1M
Avg Qtr Burn
-17.38M
Short % of Float
11.47%
Insider Ownership
23.24%
Institutional Own.
32.49%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CT-0508 (HER2) + pembrolizumab Details Solid tumor/s, Cancer | Phase 1 Data readout | |
CT-0508 (HER2) Details Solid tumor/s, Cancer | Phase 1 Update | |
CT-0525 Details Solid tumor/s, Cancer | Phase 1 Initiation | |
Vicineum™ Details Bladder cancer, Cancer | Failed Discontinued | |
Vicineum™ Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued |